Skip to main content
Smart Investors Daily
Baxter International Inc. logo

NYSE · BAX

Baxter International Inc.

Healthcare · Medical - Instruments & Supplies

$25.39

Down-$0.77 (-2.94%)

Updated Nov 20, 2026, 2:01 AM

SID Score

6.3/10

Composite research score

Smart Money

47/100

Neutral

Market cap
9.71B
P/E ratio
-28.49
Dividend yield
2.05%
52-week range
$15.73 – $30.00
Volume
4.67M
Avg. volume
7.88M

Price performance · BAX

BAX price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Nov 19, 2026

BAX closed at $25.39 after 21 trading sessions, down 1.01% for the selected period.

Last close
$25.39
Period change
-1.01%
Period low
$23.00
Period high
$26.50
Daily close
View OHLC price history
BAX OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Nov 19, 2026$26.10$26.16$25.13$25.394.67M
Nov 18, 2026$25.56$26.46$25.52$26.164.01M
Nov 17, 2026$25.41$25.94$25.12$25.764.17M
Nov 16, 2026$25.79$26.13$25.505$25.546.16M
Nov 13, 2026$25.90$25.90$25.43$25.814.49M
Nov 12, 2026$26.595$26.66$25.645$25.744.67M
Nov 11, 2026$26.11$26.50$25.98$26.343.83M
Nov 10, 2026$26.18$26.49$25.57$26.423.83M
Nov 9, 2026$26.17$26.706$25.87$26.414.54M
Nov 6, 2026$24.99$25.825$24.7615$25.796.2M
Nov 5, 2026$26.82$26.97$25.09$25.6510.1M
Nov 4, 2026$26.24$27.085$25.87$26.5010.49M
Nov 3, 2026$24.04$25.57$23.90$25.499.4M
Nov 2, 2026$23.34$24.25$23.265$24.2210.16M
Oct 30, 2026$23.59$23.59$22.495$23.0011.82M
Oct 29, 2026$26.00$26.10$23.37$23.5015.67M
Oct 28, 2026$25.11$26.025$24.93$25.4612.43M
Oct 27, 2026$25.20$25.25$24.81$24.925.49M
Oct 26, 2026$25.62$25.62$25.06$25.294.04M
Oct 23, 2026$25.71$25.71$25.20$25.304.94M
Oct 22, 2026$24.73$25.705$24.68$25.655.21M

Latest BAX news

The latest Smart Investors Daily articles mentioning BAX.

BAX research

Overview

Company profile and research snapshot.

Company profile

Baxter offers a variety of medical supplies and equipment to providers. From its legacy operations, Baxter sells injectable therapies for use in care settings, including IV pumps, administrative sets, and solutions; nutritional products; and surgical sealants and hemostatic agents. Baxter expanded its portfolio of hospital-focused offerings by acquiring Hillrom in late 2021, which added basic equipment like hospital beds, operating room equipment, and patient monitoring tools to the portfolio. Baxter also sold its kidney care tools in early 2025.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
—
Average target
$23.80
Implied upside
—
Analysts
—
BAX recent ratings
DateFirmRatingTarget
Nov 9, 2026BarclaysUnderweight—
Oct 30, 2026JP MorganNeutral—
Oct 30, 2026Wells FargoEqual-Weight—
Oct 7, 2026BarclaysUnderweight—
Oct 5, 2026CitigroupNeutral—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Nov 6, 2026

How Return To Profit Will Impact Baxter International Stock (BAX)

Baxter International reported third quarter 2026 sales of US$2,976 million and net income of US$294 million, and raised its full year sales growth guidance from 4% to 5% from continuing operations. The return to profit over both the quarter and nine month period suggests Baxter International cost actions and portfolio work are starting to show through in reported earnings from continuing operations. This article examines how Baxter International's investment narrative intersects with its...

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.